Select Equity Group L.P. Boosts Stock Position in Certara, Inc. $CERT

Select Equity Group L.P. lifted its stake in shares of Certara, Inc. (NASDAQ:CERT - Free Report) by 534.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,094,495 shares of the company's stock after purchasing an additional 922,007 shares during the quarter. Select Equity Group L.P. owned about 0.67% of Certara worth $10,836,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Janney Montgomery Scott LLC purchased a new stake in shares of Certara during the first quarter worth approximately $120,000. First Trust Advisors LP acquired a new position in Certara during the fourth quarter worth $140,000. Illinois Municipal Retirement Fund grew its holdings in Certara by 3.9% during the first quarter. Illinois Municipal Retirement Fund now owns 59,721 shares of the company's stock worth $591,000 after acquiring an additional 2,268 shares during the period. Northern Trust Corp grew its holdings in Certara by 4.5% during the first quarter. Northern Trust Corp now owns 916,299 shares of the company's stock worth $9,071,000 after acquiring an additional 39,289 shares during the period. Finally, Brown Advisory Inc. acquired a new position in Certara during the first quarter worth $238,000. Hedge funds and other institutional investors own 73.96% of the company's stock.

Certara Trading Up 3.3%

Shares of NASDAQ CERT traded up $0.36 during midday trading on Friday, hitting $11.28. The stock had a trading volume of 2,057,903 shares, compared to its average volume of 1,264,191. The company has a market capitalization of $1.81 billion, a price-to-earnings ratio of 225.65 and a beta of 1.43. The company has a quick ratio of 2.16, a current ratio of 2.16 and a debt-to-equity ratio of 0.27. Certara, Inc. has a 1-year low of $8.64 and a 1-year high of $15.69. The company has a fifty day moving average price of $10.73 and a 200 day moving average price of $11.28.

Certara (NASDAQ:CERT - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). The company had revenue of $104.57 million for the quarter, compared to analysts' expectations of $104.14 million. Certara had a net margin of 1.97% and a return on equity of 5.11%. The business's quarterly revenue was up 12.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.07 earnings per share. On average, analysts predict that Certara, Inc. will post 0.28 earnings per share for the current year.

Insider Activity at Certara

In related news, insider Leif E. Pedersen sold 51,224 shares of the firm's stock in a transaction dated Tuesday, September 9th. The stock was sold at an average price of $10.92, for a total transaction of $559,366.08. Following the sale, the insider directly owned 73,979 shares in the company, valued at approximately $807,850.68. This trade represents a 40.91% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 2.33% of the company's stock.

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. Morgan Stanley assumed coverage on Certara in a report on Thursday, July 3rd. They set an "equal weight" rating and a $16.00 price objective on the stock. Zacks Research upgraded Certara from a "strong sell" rating to a "hold" rating in a research report on Friday, September 5th. UBS Group dropped their target price on shares of Certara from $17.50 to $15.00 and set a "buy" rating for the company in a report on Thursday, August 7th. Finally, KeyCorp cut their target price on shares of Certara from $18.00 to $15.00 and set an "overweight" rating for the company in a research report on Monday, July 14th. Five research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $15.14.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.